Amgen CEO expects 25% of growth to come from Asia in next decade MD bureau16 Jan 2020 1:28 PM ISTSAN FRANCISCO: Biotechnology giant Amgen Inc expects up to a quarter of its growth to come from Asia over the next decade, Chief Executive Officer...
Novartis gets U.S. nod for long-delayed copycat version of Amgen billion seller Neulasta drug Medical Dialogues Bureau6 Nov 2019 10:32 AM ISTZURICH: Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen's $4 billion seller Neulasta drug, helping the Swiss drugmaker in...
Amgen to reduce price of its cholesterol drug Repatha starting 2020 Medical Dialogues Bureau3 Nov 2019 9:15 AM ISTAmgen launched the lower-price option of Repatha last October, selling the drug to some patients under the list price of $5,850 per year because the...
Mirati Therapeutics oral drug MRTX849 shrinks tumours in early-stage trial Medical Dialogues Bureau2 Nov 2019 9:00 AM ISTOut of 17 patients enrolled in the Phase 1 trial of Mirati Therapeutics' oral drug MRTX849, 12 have been evaluated, including six with lung cancer and...
Dr Reddys gets CDSCO Committee recommendation for approval for additional indications of Desosumab Farhat Nasim26 Oct 2019 2:38 PM ISTRecently, the Hyderabad-based Dr Reddy's Labs presented its proposal before the CDSCO Committee for an additional indication for Denosumab 120...
Amgen challenges Alexion Pharma blood disorder treatment Soliris in US patent court Medical Dialogues Bureau2 Sept 2019 9:30 AM ISTThe IPR is seeking to invalidate new patents covering the composition of the main ingredient of Soliris, eculizumab, its formulation, and its use to...
Lupin gets USFDA nod for generic versions of Sensipar tablets, Omidria intraocular solution Medical Dialogues Bureau4 July 2019 9:45 AM ISTCinacalcet tablets are a generic version of Amgen Inc's Sensipar tablets in the same strengths, said Lupin.New Delhi: Drug firm Lupin on Wednesday...
Sanofi loses German patent case against Amgen over cholesterol drug Praluent Medical Dialogues Bureau9 Jun 2019 9:30 AM ISTIn the latest setback for Sanofi in the drawn-out patent dispute with Amgen, which is selling its rival drug Repatha, the German court ruled that...
Eli Lilly new migraine drug Emgality pulls ahead of Amgen in battle for prescriptions Farhat Nasim12 May 2019 9:30 AM ISTWeekly U.S. prescription data from IQVIA, an analytics provider to the life sciences industry, showed that Lilly's therapy Emgality claimed the...
Cipla to launch Cinacalcet Hydrochloride tablets, a generic version of Sensipar Farhat Nasim7 March 2019 9:30 AM ISTCipla said, its cinacalcet hydrochloride tablets in the strengths of 30mg, 60mg and 90mg) is generic therapeutic equivalent version of Sensipar, a...
Novartis Aimovig not cost effective: UK price watchdog Medical Dialogues Bureau11 Jan 2019 9:00 AM ISTNovartis, whose U.K. price for Aimovig is about 5,000 pounds ($6,374) annually but which was offering discounts, is counting on the medicine to be a...
Regeneron third-quarter profit easily tops Street view on Eylea, Dupixent sales Ruby Khatun Khatun11 Nov 2017 9:30 AM ISTRegeneron Pharmaceuticals Inc on Wednesday reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand...
